Canlyniadau Chwilio - KRISTELEIT, REBECCA

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 gan Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA gan WOLFORD, JULIET E., BAI, JIARU, MOORE, KATHLEEN N., KRISTELEIT, REBECCA, MONK, BRADLEY J., TEWARI, KRISHNANSU S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors gan Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy gan Milani, Andrea, Kristeleit, Rebecca, McCormack, Mary, Raja, Fharat, Luvero, Daniela, Widschwendter, Martin, MacDonald, Nicola, Mould, Tim, Olatain, Adeola, Hackshaw, Allan, Ledermann, Jonathan A

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts gan Chung, Yuen-Li, Troy, Helen, Kristeleit, Rebecca, Aherne, Wynne, Jackson, L Elizabeth, Atadja, Peter, Griffiths, John R, Judson, Ian R, Workman, Paul, Leach, Martin O, Beloueche-Babari, Mounia

Cael y testun llawn Cael y testun llawn

An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials gan Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies gan Osborn, Gabriel, Stavraka, Chara, Adams, Rebecca, Sayasneh, Ahmad, Ghosh, Sharmistha, Montes, Ana, Lacy, Katie E, Kristeleit, Rebecca, Spicer, James, Josephs, Debra H, Arnold, James N, Karagiannis, Sophia N

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study gan Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors gan Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors gan Brunetto, André T., Ang, Joo Ern, Lal, Rohit, Olmos, David, Molife, L. Rhoda, Kristeleit, Rebecca, Parker, Ann, Casamayor, Isabel, Olaleye, Muyibat, Mais, Anna, Hauns, Bernhard, Strobel, Vera, Hentsch, Bernd, de Bono, Johann S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours gan Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours gan Bono, Petri, Massard, Christophe, Peltola, Katriina J, Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S, Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V J, Rodon, Jordi A

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Detection of circulating tumour cell clusters in human glioblastoma gan Krol, Ilona, Castro-Giner, Francesc, Maurer, Martina, Gkountela, Sofia, Szczerba, Barbara Maria, Scherrer, Ramona, Coleman, Niamh, Carreira, Suzanne, Bachmann, Felix, Anderson, Stephanie, Engelhardt, Marc, Lane, Heidi, Evans, Thomas Ronald Jeffry, Plummer, Ruth, Kristeleit, Rebecca, Lopez, Juanita, Aceto, Nicola

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment gan Rolfo, Christian, Isambert, Nicolas, Italiano, Antoine, Molife, L. Rhoda, Schellens, Jan H.M., Blay, Jean‐Yves, Decaens, Thomas, Kristeleit, Rebecca, Rosmorduc, Olivier, Demlova, Regina, Lee, Myung‐Ah, Ravaud, Alain, Kopeckova, Katerina, Learoyd, Maria, Bannister, Wendy, Locker, Gershon, de Vos‐Geelen, Judith

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... gan Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

Cael y testun llawn Cael y testun llawn Cael y testun llawn

First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors gan Sarker, Debashis, Ang, Joo Ern, Baird, Richard, Kristeleit, Rebecca, Shah, Krunal, Moreno, Victor, Clarke, Paul A., Raynaud, Florence I., Levy, Gallia, Ware, Joseph A, Mazina, Kathryn, Lin, Ray, Wu, Jenny, Fredrickson, Jill, Spoerke, Jill M, Lackner, Mark R, Yan, Yibing, Friedman, Lori S., Kaye, Stan B., Derynck, Mika K., Workman, Paul, de Bono, Johann S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as mainten... gan Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours gan Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, Lopez, Juanita

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer gan Oza, Amit, Matulonis, Ursula, Alvarez Secord, Angeles, Roman, Lynda, Blagden, Sarah, Banerjee, Susana, Nemunaitis, John, McGuire, William, Ghamande, Sharad, Birrer, Michael, Fleming, Gini F, Jennifer Markham, Merry, Hirte, Hal, Provencher, Diane, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah, Schwartz, Benjamin, Braly, Patricia, Hall, Geoffrey, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre gan Russell, Beth, Moss, Charlotte, Tsotra, Eirini, Gousis, Charalampos, Josephs, Debra, Enting, Deborah, Karampera, Christina, Khan, Muhammad, Roca, Jose, Sita-Lumsden, Ailsa, Owczarczyk, Kasia, Wylie, Harriet, Haire, Anna, Smith, Daniel, Zaki, Kamarul, Swampillai, Angela, Lei, Mary, Manik, Vishal, Michalarea, Vasiliki, Kristeleit, Rebecca, Mera, Anca, Sawyer, Elinor, Flanders, Lucy, De Francesco, Irene, Papa, Sophie, Ross, Paul, Spicer, James, Dann, Bill, Jogia, Vikash, Shaunak, Nisha, Kristeleit, Hartmut, Rigg, Anne, Montes, Ana, Van Hemelrijck, Mieke, Dolly, Saoirse

Cael y testun llawn Cael y testun llawn Cael y testun llawn